SOURCE: Plandai Biotechnology, Inc.
NEW YORK, NY--(Marketwired - Mar 26, 2014) - What may have been lost in Plandaí Biotechnology's (OTCQB: PLPL) recently reported results from its human clinical trial to test the anti-aging properties of Phytofare™, is that the "statistically significant" results are themselves extremely significant to the future of the company. First and foremost, the results delivered in this human trial using Plandaí's Phytofare™ Catechin Complex show "proof of concept," and for investors, that proof should turn out to be no small thing when it comes to the future success of this company.
Proof of concept is vital to any new product, and it means that the company's claims of higher bioavailability with their Phytofare products are validated on the ultimate stage -- a human clinical trial. These results could lead Plandaí's distribution partners to use Phytofare™ Catechin Complex in wide range of cosmetic products from moisturizers to shampoos to hand and face creams among many others. The more products these distributors can put Phytofare™ Catechin Complex into, the more product Plandaí can deliver to partners.
According to Plandaí, the data from this double-blind study showed that Phytofare yielded "statistically significant" results when compared to a baseline product. The trial involved 35 Caucasian women who applied 2 topical creams daily, one of which contained Plandaí's Phytofare™, to patches of their skin. The women then had their skin tested for scaling and roughness, skin hydration, and skin elasticity at 14, 28, and 42 days.
In the tested areas, the study showed that the addition of Phytofare:
- Improved skin roughness by as much as 15% at 28 days
- Reduced scaliness of the top layer of skin by 20%
Both of these measures were deemed "statistically significant" by Professor Banie Boneschans of North West University in Potchefstroom, South Africa, one of the leading research universities on the continent, who conducted the trial. Additionally the study showed:
- Phytofare increased skin hydration by 15% at both 28 and 42 days, compared to .9% and 7.8% for the base product. The study pointed out that skin hydration improved significantly at 28 days and maintained that level throughout the study.
- An average improvement in skin elasticity of 1% at 42 days
What Plandaí has shown in this trial is very good news for investors. Any successful human clinical trial should be viewed as significant, and these results should impress the company's partners significantly.
About Stock Market Media Group
SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. SMMG is compensated for Plandaí articles, reports and interviews by a third party who reserves the right to sell securities at any time before, during, or after the publication of this article. To date, SMMG has received total compensation of $36,290, for content related to Plandaí. For more information and to read full disclaimers and disclosures: www.stockmarketmediagroup.com/disclaimer.